Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

CAR-T Digest - August 2020

Weekly Digest - July 2026

06 July 2026: Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis has agreed to acquire Myricx Bio to strengthen its next-generation antibody-drug conjugate (ADC) portfolio with a first-in-class NMTi payload platform, expanding its oncology pipeline with differentiated payload technology designed to overcome resistance and improve outcomes for patients with cancer
The acquisition brings Myricx Bio’s proprietary NMTi payload platform together with its two lead preclinical ADC candidates, broadening Novartis’ pipeline with innovative therapies that have the potential to address multiple solid tumor types through a differentiated mechanism of action
Myricx’s NMTi payload technology represents a novel ADC approach that selectively inhibits N-myristoyltransferase within tumor cells, with the potential to overcome the limitations of conventional payloads, expand the therapeutic window, and improve treatment durability
By combining Novartis’ global oncology expertise with Myricx’s innovative ADC platform, the acquisition is expected to accelerate the development of next-generation ADCs and broaden the application of targeted therapies across diverse solid tumor settings
Strategically, the acquisition reinforces Novartis’ commitment to advancing next-generation ADC innovation through differentiated payload technologies, strengthening its precision oncology portfolio and positioning the company at the forefront of developing novel ADCs capable of addressing resistance to existing therapies